Get notified of page updates
Glossary on
off
Printer Friendly Page
A Study of the Drug REC-4881 For Treating People with Advanced Cancers with an APC or AXIN1 Mutation
Clinicaltrials.gov identifier:
NCT06005974
Treatment study for people with advanced cancer with an APC or AXIN1 mutation
A Study of the Drug REC-4881 For Treating People with Advanced Cancers with an APC or AXIN1 Mutation
About the Study
This study is looking at how well the research drug REC-4881 works and how safe it is for the treatment of people with advanced or cancers with an or AXIN1 mutation. REC-4881 is a type of drug known as a MEK1/2 inhibitor.
NOTE: This study is no longer recruiting patients.
This Study is Open To:
NOTE: This study is no longer recruiting patients.
This Study is Not Open To:
NOTE: This study is no longer recruiting patients.